128 related articles for article (PubMed ID: 36689697)
1. Clinicopathologic and Molecular Analysis of Normal Karyotype Therapy-Related and De Novo Acute Myeloid Leukemia: A Multi-Institutional Study by the Bone Marrow Pathology Group.
Cantu MD; Kanagal-Shamanna R; Wang SA; Kadia T; Bueso-Ramos CE; Patel SS; Geyer JT; Tam W; Madanat Y; Li P; George TI; Nichols MM; Rogers HJ; Liu YC; Aggarwal N; Kurzer JH; Maracaja DLV; Hsi ED; Zaiem F; Babu D; Foucar K; Laczko D; Bagg A; Orazi A; Arber DA; Hasserjian RP; Weinberg OK
JCO Precis Oncol; 2023 Jan; 7():e2200400. PubMed ID: 36689697
[TBL] [Abstract][Full Text] [Related]
2. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
[TBL] [Abstract][Full Text] [Related]
3. Complex karyotype but not other cytogenetic abnormalities is associated with worse posttransplant survival of patients with nucleophosmin 1-mutated acute myeloid leukemia: A study from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party.
Moukalled N; Labopin M; Versluis J; Socié G; Blaise D; Salmenniemi U; Rambaldi A; Gedde-Dahl T; Tholouli E; Kröger N; Bourhis JH; Von Dem Borne P; Daguindau E; Forcade E; Nagler A; Esteve J; Ciceri F; Bazarbachi A; Mohty M
Am J Hematol; 2024 Mar; 99(3):360-369. PubMed ID: 38165072
[TBL] [Abstract][Full Text] [Related]
4. Chromosomal Abnormalities and Prognosis in
Angenendt L; Röllig C; Montesinos P; Martínez-Cuadrón D; Barragan E; García R; Botella C; Martínez P; Ravandi F; Kadia T; Kantarjian HM; Cortes J; Juliusson G; Lazarevic V; Höglund M; Lehmann S; Recher C; Pigneux A; Bertoli S; Dumas PY; Dombret H; Preudhomme C; Micol JB; Terré C; Ráčil Z; Novák J; Žák P; Wei AH; Tiong IS; Wall M; Estey E; Shaw C; Exeler R; Wagenführ L; Stölzel F; Thiede C; Stelljes M; Lenz G; Mikesch JH; Serve H; Ehninger G; Berdel WE; Kramer M; Krug U; Schliemann C
J Clin Oncol; 2019 Oct; 37(29):2632-2642. PubMed ID: 31430225
[TBL] [Abstract][Full Text] [Related]
5. What Is Abnormal in Normal Karyotype Acute Myeloid Leukemia in Children? Analysis of the Mutational Landscape and Prognosis of the TARGET-AML Cohort.
Herlin MK; Yones SA; Kjeldsen E; Holmfeldt L; Hasle H
Genes (Basel); 2021 May; 12(6):. PubMed ID: 34064268
[TBL] [Abstract][Full Text] [Related]
6. Overlapping features of therapy-related and de novo NPM1-mutated AML.
Othman J; Meggendorfer M; Tiacci E; Thiede C; Schlenk R; Dillon R; Stasik S; Venanzi A; Bertoli S; Delabesse E; Dumas PY; Pigneux A; Bidet A; Gilkes AF; Thomas I; Voso MT; Rambaldi A; Brunetti L; Perriello VM; Andresen V; Gjertsen BT; Martelli MP; Récher C; Röllig C; Bornhäuser M; Serve H; Müller-Tidow C; Baldus CD; Haferlach T; Russell N; Falini B
Blood; 2023 Apr; 141(15):1846-1857. PubMed ID: 36508705
[TBL] [Abstract][Full Text] [Related]
7. Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study.
Rogers HJ; Wang X; Xie Y; Davis AR; Thakral B; Wang SA; Borthakur G; Cantu MD; Margolskee EM; Philip JKS; Sukhanova M; Bagg A; Bueso-Ramos CE; Orazi A; Arber DA; Hsi ED; Hasserjian RP
Am J Hematol; 2020 Jul; 95(7):799-808. PubMed ID: 32249963
[TBL] [Abstract][Full Text] [Related]
8. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
[TBL] [Abstract][Full Text] [Related]
9. Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome.
Mason EF; Hasserjian RP; Aggarwal N; Seegmiller AC; Pozdnyakova O
Blood Adv; 2019 Nov; 3(21):3322-3332. PubMed ID: 31698462
[TBL] [Abstract][Full Text] [Related]
10. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
[TBL] [Abstract][Full Text] [Related]
11. Myeloid sarcoma with
Ramia de Cap M; Wu LP; Hirt C; Pihan GA; Patel SS; Tam W; Bueso-Ramos CE; Kanagal-Shamanna R; Raess PW; Siddon A; Narayanan D; Morgan EA; Pinkus GS; Mason EF; Hsi ED; Rogers HJ; Toth L; Foucar K; Hurwitz SN; Bagg A; Rets A; George TI; Orazi A; Arber DA; Hasserjian RP; Weinberg OK;
Leuk Lymphoma; 2023 May; 64(5):972-980. PubMed ID: 36960680
[TBL] [Abstract][Full Text] [Related]
12. High WT1 expression predicted induction chemotherapy failure in acute myeloid leukemia patients with non-favorable cytogenetic risk.
Xu N; Chen WM; Li LD; Long LY; Wang X; Jiang Q; Jiang H; Huang XJ; Qin YZ
Clin Exp Med; 2023 Oct; 23(6):2629-2638. PubMed ID: 36637581
[TBL] [Abstract][Full Text] [Related]
13. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
14. Combination of FLT3-ITD Allelic Ratio, NPM1 Mutation, and Immunophenotypic Markers to Modulate Outcome Prediction in Patients with Normal Karyotype Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation.
Jiang G; Capo-Chichi JM; Liu A; Atenafu EG; Kumar R; Minden MD; Chang H
Biol Blood Marrow Transplant; 2020 Nov; 26(11):1995-2000. PubMed ID: 32712325
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of NPM1 mutations in Serbian adult patients with acute myeloid leukemia.
Kuzmanovic M; Tosic N; Colovic N; Karan-Djurasevic T; Spasovski V; Radmilovic M; Nikcevic G; Suvajdzic-Vukovic N; Tomin D; Vidovic A; Virijevic M; Pavlovic S; Colovic M
Acta Haematol; 2012; 128(4):203-12. PubMed ID: 22906848
[TBL] [Abstract][Full Text] [Related]
16. Cytogenetic abnormalities in
Fu W; Huang A; Xu L; Peng Y; Gao L; Chen L; Chen J; Tang G; Yang J; Ni X
Leuk Lymphoma; 2022 Aug; 63(8):1956-1963. PubMed ID: 35227153
[No Abstract] [Full Text] [Related]
17. Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse.
Wang ES; Sait SN; Gold D; Mashtare T; Starostik P; Ford LA; Wetzler M; Nowak NJ; Deeb G
Cancer Genet Cytogenet; 2010 Oct; 202(2):101-7. PubMed ID: 20875872
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.
Port M; Böttcher M; Thol F; Ganser A; Schlenk R; Wasem J; Neumann A; Pouryamout L
Ann Hematol; 2014 Aug; 93(8):1279-86. PubMed ID: 24801015
[TBL] [Abstract][Full Text] [Related]
19. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.
Schnittger S; Schoch C; Kern W; Mecucci C; Tschulik C; Martelli MF; Haferlach T; Hiddemann W; Falini B
Blood; 2005 Dec; 106(12):3733-9. PubMed ID: 16076867
[TBL] [Abstract][Full Text] [Related]
20. The clinicopathologic significance of NPM1 mutation and ability to detect mutated NPM1 by immunohistochemistry in non-AML myeloid neoplasms.
Kaseb H; Visconte V; Socha DS; Crane GM; Durkin L; Cook JR; Maciejewski JP; Hsi ED; Rogers HJ
Genes Chromosomes Cancer; 2023 Oct; 62(10):573-580. PubMed ID: 36959701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
